Breakthrough COVID-19 Cases Raise Concern Over B.1.617 Variant
CEPI Offers Testing Against Variants Of Concern
As the B.1.617 variant of SARS-CoV-2 spreads to countries including the UK and US after having caused havoc in India, vaccine effectiveness against this variant is under the lens with breakthrough cases reported post full vaccination. Meanwhile, CEPI’s offer to help in testing against variants has potential to harmonize assessment of COVID-19 vaccines performance.
You may also be interested in...
Agency inspectors worked in the country for about a month before the coronavirus infection surge forced another halt.
A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.
As the World Health Organization brands the Indian virus a “variant of concern,” the UK is planning to use a lab-grown virus variant in challenge trials of current and new vaccines, and is also investing in new variant vaccine testing facilities. A new study will use Oxford Immunotec’s T cell test to monitor people’s immunological response to infection or vaccination.